UO
University of Cambridge
University of Cambridge is a seed to Series C stage investment firm. It has made 9 investments. 33% of their portfolio is in Biotech & Life Sciences. They made 1 investment in the last 12 months. Their most common stage is series-a (50% of deals).
Portfolio
9
Fund Size
—
Top Stage
Series A
Last 12 Mo
1
Team
AM
Anne Marie Fleurbaaij
Managing Director, Marketable Assets
SS
Sam Sturge
Managing Director
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
12 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 T-Therapeutics | Series A | $91M | Nov 2025 |
 Paragraf | Series C | — | Jan 2025 |
| T-Therapeutics | Series A | — | Nov 2023 |
 Materials Nexus | Unknown | — | Jul 2023 |
| T-Therapeutics | Series A | — | Jan 2023 |
| Materials Nexus | Seed | — | Jan 2023 |
| CCambridge Epigenetix | Series B | $21M | Jan 2016 |
| NNobacz Healthcare | Unknown | — | — |
 Echion Technologies | Series A | — | — |
 Nobacz | Unknown | — | — |
| EEchion | Series A | — | — |
 Riverlane | Series A | — | — |
Top Co-Investors
Cambridge Enterprise4 shared
Cambridge Innovation Capital4 shared
Parkwalk Advisors3 shared
BGF3 shared
Sanofi Ventures3 shared
F-Prime Capital3 shared
Fidelity Investments3 shared
Sofinnova Partners3 shared
Digitalis Ventures3 shared
Adjuvo2 shared
The Yield Lab2 shared
ACF Investors2 shared
Cambridge Angels2 shared
Origin Ventures2 shared
CBMM2 shared
Molten Ventures2 shared
Amadeus Capital Partners2 shared
MD One Ventures2 shared
High-Tech Gründerfonds2 shared
Sequoia Capital1 shared
Last updated: 20 October 2026